Abstract:Sitafloxacin is one of the newer generation fluoroquinolones. Considering the ever-changing antimicrobial resistance, it is necessary to monitor the activities of sitafloxacin against recent pathogenic isolates. Therefore, we determined the minimum inhibitory concentrations (MICs) of sitafloxacin and comparators by broth microdilution or agar dilution method against 1101 clinical isolates collected from 2017 to 2019 in 31 hospitals across China. Sitafloxacin was highly active against gram-positive isolates evidenced by the MICs required to inhibit the growth of 50%/90% isolates (MIC50/90): <= 0.03/0.25, <= 0.03/0.125, <= 0.03/2, 0.125/0.25, 0.25/2, and 0.125/0.125 mg/L for methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-susceptible coagulase-negative Staphylococcus (MSCNS), methicillin-resistant S. aureus (MRSA), methicillin-resistant CNS, Enterococcus faecalis, and Streptococcus pneumoniae, respectively. Sitafloxacin inhibited 82.8% of the MRSA strains and 97.5% of MRCNS strains. Sitafloxacin was also potent against ciprofloxacin-susceptible Escherichia coli (MIC50/90: <= 0.03/0.06 mg/L) and Klebsiella pneumoniae (MIC50/90: <= 0.03/0.125 mg/L), non-ESBL-producing E. coli (MIC50/90: <= 0.03/1 mg/L) and K. pneumoniae (MIC50/90: <= 0.03/0.5 mg/L), Haemophilus influenzae (MIC50/90: <= 0.015/0.06 mg/L), Haemophilus parainfluenzae (MIC50/90: 0.125/0.5 mg/L), Moraxella catarrhalis (MIC50/90: <= 0.015/<= 0.015 mg/L), Bacteroides fragilis (MIC50/90: 0.06/2 mg/L), Peptostreptococcus (MIC50/90: 0.125/4 mg/L), and Mycoplasma pneumoniae (<= 0.03/<= 0.03 mg/L). However, sitafloxacin was less active for Enterococcus faecium, ciprofloxacin-resistant and/or ESBL-producing E. coli, and K. pneumoniae strains. Sitafloxacin was superior or comparable to most of the comparators in activities against the abovementioned isolates, so sitafloxacin is still highly active against most of the clinical isolates in hospitals across China, proving its utility in treatment of the abovementioned susceptible strains.

Sitafloxacin Expresses Potent Anti-<i>Mycobacterium abscessus</i> Activity

Sitafloxacin Expresses Potent Anti-Mycobacterium abscessus Activity

Comparative Activities of Sitafloxacin Against Recent Clinical Isolates in Hospitals Across China

A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity In Vitro

Sitafloxacin Pharmacokinetics/pharmacodynamics Against Multidrug-Resistant Bacteria in a Dynamic Urinary Tract Infection in Vitro Model.

Activity of sitafloxacin against extracellular and intracellular Staphylococcus aureus in vitro and in vivo : comparison with levofloxacin and moxifloxacin

Antibacterial activity of the novel oxazolidinone contezolid (MRX-I) against Mycobacterium abscessus

Antimicrobial activities of sitafloxacin and comparators against the clinical isolates of less common nonfermenting Gram-negative bacteria

Antibacterial Mechanisms and Clinical Impact of Sitafloxacin

In Vitro Activity of Rifabutin Against Mycobacterium Abscessus, Clinical Isolates.

Evaluation of the Antibacterial Effect in Vitro of Moxifloxacin and Linezolid on Nontuberculous Mycobacterium.

New generation fluoroquinolone sitafloxacin could potentially overcome the majority levofloxacin and moxifloxacin resistance in multidrug-resistant Mycobacterium tuberculosis

Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections

Sulbactam Enhances the in Vitro Activity of Sitafloxacin Against Extensively-Drug Resistant Acinetobacter Baumannii

[In Vitro Evaluation of the Antibacterial Activity of Nemonoxacin Against Mycobacterium Abscessus].

Activity of Oritavancin and Its Synergy with Other Antibiotics against Mycobacterium abscessus Infection In Vitro and In Vivo

Antimicrobial and Antibiofilm Effects of Bithionol against Mycobacterium abscessus

Ar-12 Exhibits Direct And Host-Targeted Antibacterial Activity Toward Mycobacterium Abscessus

Efflux pump effects on levofloxacin resistance in Mycobacterium abscessus

Identification of Essential Oils with Strong Activity Against Stationary Phase Mycobacterium Abscessus

Antibacterial activity of the novel compound Sudapyridine (WX-081) against Mycobacterium abscessus